Fibrinogen as a key regulator of inflammation in disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Degen JL (1999) Hemostatic factors and inflammatory disease. Thromb Haemost 82(2):858–864
Degen JL, Drew AF, Palumbo JS, Kombrinck KW, Bezerra JA, Danton MJ, Holmback K, Suh TT (2001) Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci 936:276–290
Doolittle RF (2009) Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb Symp Quant Biol 74:35–40
Macfarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202:498–499
Schoenmakers SH, Reitsma PH, Spek CA (2005) Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 34(1):30–37
Adams RL, Bird RJ (2009) Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton) 14(5):462–470
Lippi G, Favaloro EJ, Franchini M, Guidi GC (2009) Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 35(1):9–22
Cimmino G, D’Amico C, Vaccaro V, D’Anna M, Golino P (2011) The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor? Expert Rev Cardiovasc Ther 9(4):517–523
Strukova SM (2001) Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc) 66(1):8–18
Licari LG, Kovacic JP (2009) Thrombin physiology and pathophysiology. J Vet Emerg Crit Care (San Antonio) 19(1):11–22
Drake WT, Lopes NN, Fenton JW 2nd, Issekutz AC (1992) Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration. Lab Invest 67(5):617–627
Sower LE, Froelich CJ, Carney DH, Fenton JW 2nd, Klimpel GR (1995) Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 155(2):895–901
Anrather D, Millan MT, Palmetshofer A, Robson SC, Geczy C, Ritchie AJ, Bach FH, Ewenstein BM (1997) Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol 159(11):5620–5628
Szaba FM, Smiley ST (2002) Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99(3):1053–1059
Serra MF, Diaz BL, Barreto EO, Cordeiro RS, Nazare Meirelles MN, Williams TJ, Martins MA, Silva PM (2000) Mechanism underlying acute resident leukocyte disappearance induced by immunological and non-immunological stimuli in rats: evidence for a role for the coagulation system. Inflamm Res 49(12):708–713
Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L (2008) Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 99(2):305–315
Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M (2008) Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 83(6):1309–1322
Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins PN, Pepys MB (2007) Human plasma fibrinogen is synthesized in the liver. Blood 109(5):1971–1974
Miller LL, Bly CG, Watson ML, Bale WF (1951) The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14. J Exp Med 94(5):431–453
Hall CE, Slayter HS (1959) The fibrinogen molecule: its size, shape, and mode of polymerization. J Biophys Biochem Cytol 5(1):11–16
Fuss C, Palmaz JC, Sprague EA (2001) Fibrinogen: structure, function, and surface interactions. J Vasc Interv Radiol 12(6):677–682
Kollman JM, Pandi L, Sawaya MR, Riley M, Doolittle RF (2009) Crystal structure of human fibrinogen. Biochemistry 48(18):3877–3886
Doolittle RF, Spraggon G, Everse SJ (1998) Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol 8(6):792–798
Yang Z, Mochalkin I, Veerapandian L, Riley M, Doolittle RF (2000) Crystal structure of native chicken fibrinogen at 5.5-A resolution. Proc Natl Acad Sci USA 97(8):3907–3912
Brown JH, Volkmann N, Jun G, Henschen-Edman AH, Cohen C (2000) The crystal structure of modified bovine fibrinogen. Proc Natl Acad Sci USA 97(1):85–90
Doolittle RF, Yang Z, Mochalkin I (2001) Crystal structure studies on fibrinogen and fibrin. Ann N Y Acad Sci 936:31–43
Ryu JK, Davalos D, Akassoglou K (2009) Fibrinogen signal transduction in the nervous system. J Thromb Haemost 7(Suppl 1):151–154
Adams RA, Passino M, Sachs BD, Nuriel T, Akassoglou K (2004) Fibrin mechanisms and functions in nervous system pathology. Mol Interv 4(3):163–176
Lisman T, Weeterings C, de Groot PG (2005) Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci 10:2504–2517
Phillips DR, Charo IF, Parise LV, Fitzgerald LA (1988) The platelet membrane glycoprotein IIb–IIIa complex. Blood 71(4):831–843
Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL (1996) Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. EMBO J 15(21):5760–5771
Farrell DH, Thiagarajan P (1994) Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 269(1):226–231
Rooney MM, Parise LV, Lord ST (1996) Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen gamma chain C terminus. J Biol Chem 271(15):8553–8555
Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87(4):709–719
Sidelmann JJ, Gram J, Jespersen J, Kluft C (2000) Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 26(6):605–618
Asselta R, Duga S, Tenchini ML (2006) The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 4(10):2115–2129
Bugge TH, Flick MJ, Daugherty CC, Degen JL (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9(7):794–807
Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, So A (1998) Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 102(1):41–50
Akassoglou K, Kombrinck KW, Degen JL, Strickland S (2000) Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 149(5):1157–1166
Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K (2007) Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 14(27):2925–2936
Lowe GD (2005) Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 3(8):1618–1627
Skogen WF, Senior RM, Griffin GL, Wilner GD (1988) Fibrinogen-derived peptide B beta 1–42 is a multidomained neutrophil chemoattractant. Blood 71(5):1475–1479
Solovjov DA, Pluskota E, Plow EF (2005) Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 280(2):1336–1345
Ugarova TP, Yakubenko VP (2001) Recognition of fibrinogen by leukocyte integrins. Ann N Y Acad Sci 936:368–385
Lishko VK, Podolnikova NP, Yakubenko VP, Yakovlev S, Medved L, Yadav SP, Ugarova TP (2004) Multiple binding sites in fibrinogen for integrin alpha Mbeta 2 (Mac-1). J Biol Chem 279(43):44897–44906
Lishko VK, Yakubenko VP, Hertzberg KM, Grieninger G, Ugarova TP (2001) The alternatively spliced alpha(E)C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins alpha(M)beta(2) and alpha(X)beta(2). Blood 98(8):2448–2455
Ugarova TP, Lishko VK, Podolnikova NP, Okumura N, Merkulov SM, Yakubenko VP, Yee VC, Lord ST, Haas TA (2003) Sequence gamma 377–395(P2), but not gamma 190–202(P1), is the binding site for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry 42(31):9365–9373
Lishko VK, Kudryk B, Yakubenko VP, Yee VC, Ugarova TP (2002) Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen. Biochemistry 41(43):12942–12951
Fan ST, Edgington TS (1993) Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 150(7):2972–2980
Perez RL, Roman J (1995) Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J Immunol 154(4):1879–1887
Perez RL, Ritzenthaler JD, Roman J (1999) Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol 20(5):1059–1066
Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL (2004) Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 113(11):1596–1606
Tang L, Ugarova TP, Plow EF, Eaton JW (1996) Molecular determinants of acute inflammatory responses to biomaterials. J Clin Invest 97(5):1329–1334
Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, Baeza-Raja B, Martinez de Lagran M, Lafuste P, Ruiz-Bonilla V, Jardi M, Gherardi R, Christov C, Dierssen M, Carmeliet P, Degen JL, Dewerchin M, Munoz-Canoves P (2008) Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22(13):1747–1752
Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, Degen JL, Akassoglou K (2007) The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204(3):571–582
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL (2007) Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 117(11):3224–3235
Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res 70(7):2634–2643
Nham SU (1999) Characteristics of fibrinogen binding to the domain of CD11c, an alpha subunit of p150,95. Biochem Biophys Res Commun 264(3):630–634
Oki T, Kitaura J, Eto K, Lu Y, Maeda-Yamamoto M, Inagaki N, Nagai H, Yamanishi Y, Nakajima H, Kumagai H, Kitamura T (2006) Integrin alphaIIbbeta3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol 176(1):52–60
Basheer M, Schwalb H, Nesher M, Gilon D, Shefler I, Mekori YA, Shapira OM, Gorodetsky R (2010) Mast cell activation by fibrinogen-related homologous c-terminal peptides (haptides) modulates systemic blood pressure. J Allergy Clin Immunol 126(5):1041–1048
Lominadze D, Dean WL, Tyagi SC, Roberts AM (2010) Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf) 198(1):1–13
Smiley ST, King JA, Hancock WW (2001) Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167(5):2887–2894
Hodgkinson CP, Patel K, Ye S (2008) Functional Toll-like receptor 4 mutations modulate the response to fibrinogen. Thromb Haemost 100(2):301–307
Lyon C, Mill C, Tsaousi A, Williams H, George S (2011) Regulation of VSMC behavior by the cadherin–catenin complex. Front Biosci 16:644–657
Paraskevas KI, Baker DM, Vrentzos GE, Mikhailidis DP (2008) The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 122(1):1–12
Kannel WB (2005) Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40(12):1215–1220
Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F (2003) Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 38(2):374–379
McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, Ferrucci L (2005) Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 150(2):276–281
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG (2007) Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 28(3):354–362
Dalmon J, Laurent M, Courtois G (1993) The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 13(2):1183–1193
Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G (1993) The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res 21(2):289–294
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636
Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G (2006) Analysis of G(−174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59(2):211–215
Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P (1987) Fibrinogen enhances and albumin reduces RBC aggregation. Angiology 38(8):615–616
Ernst E, Matrai A, Marshall M (1988) Blood rheology in patients with transient ischemic attacks. Stroke 19(5):634–636
Coull BM, Beamer N, de Garmo P, Sexton G, Nordt F, Knox R, Seaman GV (1991) Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 22(2):162–168
Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG (1997) Blood viscosity and risk of cardiovascular events: the Edinburgh artery study. Br J Haematol 96(1):168–173
Shyy JY, Chien S (2002) Role of integrins in endothelial mechanosensing of shear stress. Circ Res 91(9):769–775
Ruggeri ZM (1993) Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost 70(1):119–123
Chiu JJ, Chien S (2011) Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91(1):327–387
Kwaan HC (2010) Role of plasma proteins in whole blood viscosity: a brief clinical review. Clin Hemorheol Microcirc 44(3):167–176
Sen U, Tyagi N, Patibandla PK, Dean WL, Tyagi SC, Roberts AM, Lominadze D (2009) Fibrinogen-induced endothelin-1 production from endothelial cells. Am J Physiol Cell Physiol 296(4):C840–C847
Patibandla PK, Tyagi N, Dean WL, Tyagi SC, Roberts AM, Lominadze D (2009) Fibrinogen induces alterations of endothelial cell tight junction proteins. J Cell Physiol 221(1):195–203
Tyagi N, Roberts AM, Dean WL, Tyagi SC, Lominadze D (2008) Fibrinogen induces endothelial cell permeability. Mol Cell Biochem 307(1–2):13–22
Bini A, Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan KL (1989) Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 9(1):109–121
Lu PP, Liu JT, Liu N, Guo F, Ji YY, Pang X (2011) Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-alpha and iNOS. Life Sci 88:839–845
Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F (1992) Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 96(2–3):227–234
Shattil SJ, Hoxie JA, Cunningham M, Brass LF (1985) Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 260(20):11107–11114
Nofer JR, Brodde MF, Kehrel BE (2010) High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 37(7):726–735
Yang H, Lang S, Zhai Z, Li L, Kahr WH, Chen P, Brkic J, Spring CM, Flick MJ, Degen JL, Freedman J, Ni H (2009) Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 114(2):425–436
Kasirer-Friede A, Kahn ML, Shattil SJ (2007) Platelet integrins and immunoreceptors. Immunol Rev 218:247–264
Relou IA, Hackeng CM, Akkerman JW, Malle E (2003) Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 60(5):961–971
Iwaki T, Sandoval-Cooper MJ, Brechmann M, Ploplis VA, Castellino FJ (2006) A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. Blood 107(10):3883–3891
Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154(3):485–490
Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667):591–594
von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C (2001) RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103(13):1772–1777
Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML, Weyrich AS, Morrow JD, Prescott SM, Zimmerman GA (2006) Expression of COX-2 in platelet–monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 116(10):2727–2738
May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M (2002) Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106(16):2111–2117
Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106(12):1523–1529
Zacharowski K, Zacharowski P, Reingruber S, Petzelbauer P (2006) Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med 84(6):469–477
Duperray A, Languino LR, Plescia J, McDowall A, Hogg N, Craig AG, Berendt AR, Altieri DC (1997) Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem 272(1):435–441
Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC (1993) Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73(7):1423–1434
Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC (1995) Regulation of leukocyte–endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci USA 92(5):1505–1509
Gorlatov S, Medved L (2002) Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. Biochemistry 41(12):4107–4116
Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, Castellino FJ, Groger M, Wolff K, Zacharowski K (2005) The fibrin-derived peptide Bbeta15–42 protects the myocardium against ischemia–reperfusion injury. Nat Med 11(3):298–304
Zacharowski K, Zacharowski PA, Friedl P, Mastan P, Koch A, Boehm O, Rother RP, Reingruber S, Henning R, Emeis JJ, Petzelbauer P (2007) The effects of the fibrin-derived peptide Bbeta(15–42) in acute and chronic rodent models of myocardial ischemia–reperfusion. Shock 27(6):631–637
Roesner JP, Petzelbauer P, Koch A, Mersmann J, Zacharowski PA, Boehm O, Reingruber S, Pasteiner W, Mascher D, Wolzt M, Barthuber C, Noldge-Schomburg GE, Scheeren TW, Zacharowski K (2007) The fibrin-derived peptide Bbeta15–42 is cardioprotective in a pig model of myocardial ischemia–reperfusion injury. Crit Care Med 35(7):1730–1735
Wiedemann D, Schneeberger S, Friedl P, Zacharowski K, Wick N, Boesch F, Margreiter R, Laufer G, Petzelbauer P, Semsroth S (2010) The fibrin-derived peptide Bbeta(15–42) significantly attenuates ischemia–reperfusion injury in a cardiac transplant model. Transplantation 89(7):824–829
Roesner JP, Petzelbauer P, Koch A, Tran N, Iber T, Vagts DA, Scheeren TW, Vollmar B, Noldge-Schomburg GE, Zacharowski K (2009) Bbeta15–42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med 37(2):598–605
Kakafika AI, Liberopoulos EN, Mikhailidis DP (2007) Fibrinogen: a predictor of vascular disease. Curr Pharm Des 13(16):1647–1659
Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M (2008) Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31(2):175–179
So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC, Busso N (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1(12):2510–2515
Weinberg JB, Pippen AM, Greenberg CS (1991) Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 34(8):996–1005
Sanchez-Pernaute O, Lopez-Armada MJ, Calvo E, Diez-Ortego I, Largo R, Egido J, Herrero-Beaumont G (2003) Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. Rheumatology (Oxford) 42(1):19–25
Liu X, Piela-Smith TH (2000) Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol 165(9):5255–5261
Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N (2000) Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis 59(10):781–787
Marty I, Peclat V, Kirdaite G, Salvi R, So A, Busso N (2001) Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest 107(5):631–640
Raghu H, Flick MJ (2011) Targeting the coagulation factor fibrinogen for arthritis therapy. Curr Pharm Biotechnol (in press)
Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M, Venables PJ (2010) Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 233(1):34–54
Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van den Berg WB, van Venrooij WJ, Joosten LA (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 48(9):2489–2500
Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, Yamamoto K (2006) Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 65(8):1013–1020
Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA (2006) Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 33(11):2115–2119
Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engstrom A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmstrom V (2010) Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 62(1):44–52
Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E (2008) Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 205(4):967–979
Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116(4):961–973
Ho PP, Lee LY, Zhao X, Tomooka BH, Paniagua RT, Sharpe O, BenBarak MJ, Chandra PE, Hueber W, Steinman L, Robinson WH (2010) Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol 184(1):379–390
Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7(1):41–53
Baeten KM, Akassoglou K (2011) Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol 71(11):1018–1039
Davalos D, Akassoglou K (2008) Imaging microglia in the central nervous system: past, present and future. In: Lane TE, Carson M, Bergmann C, Wyss-Coray T (eds) Central nervous system diseases and inflammation. Springer, USA, pp 45–57
Hawkins BT, Davis TP (2005) The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57(2):173–185
Akassoglou K, Strickland S (2002) Nervous system pathology: the fibrin perspective. Biol Chem 383(1):37–45
Preston E, Webster J, Small D (2001) Characteristics of sustained blood–brain barrier opening and tissue injury in a model for focal trauma in the rat. J Neurotrauma 18(1):83–92
Schachtrup C, Lu P, Jones LL, Lee JK, Lu J, Sachs BD, Zheng B, Akassoglou K (2007) Fibrinogen inhibits neurite outgrowth via beta3 integrin-mediated phosphorylation of the EGF receptor. Proc Natl Acad Sci USA 104(28):11814–11819
Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, Akassoglou K (2010) Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 30(17):5843–5854
Adhami F, Liao G, Morozov YM, Schloemer A, Schmithorst VJ, Lorenz JN, Dunn RS, Vorhees CV, Wills-Karp M, Degen JL, Davis RJ, Mizushima N, Rakic P, Dardzinski BJ, Holland SK, Sharp FR, Kuan C-Y (2006) Cerebral ischemia–hypoxia induces intravascular coagulation and autophagy. Am J Pathol 169(2):566–583
Schnell L, Fearn S, Klassen H, Schwab ME, Perry VH (1999) Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci 11(10):3648–3658
Akassoglou K, Yu WM, Akpinar P, Strickland S (2002) Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation. Neuron 33(6):861–875
Yoshimura A, Wakabayashi Y, Mori T (2010) Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 147(6):781–792
Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, Chin MT, Topper JN, Perrella MA, Lee ME (2000) Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem 275(47):36653–36658
Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M (2005) Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem 280(7):5491–5495
Murray V, Norrving B, Sandercock PA, Terent A, Wardlaw JM, Wester P (2010) The molecular basis of thrombolysis and its clinical application in stroke. J Intern Med 267(2):191–208
Alexandrov AV (2010) Current and future recanalization strategies for acute ischemic stroke. J Intern Med 267(2):209–219
Diamond SL (1999) Engineering design of optimal strategies for blood clot dissolution. Annu Rev Biomed Eng 1:427–462
Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J (2010) Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature 465(7297):478–482
Wang X, Lo EH (2003) Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol Neurobiol 28(3):229–244
Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ (1994) Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 25(9):1847–1853, discussion 1853–1844
Ninomia T, Wang L, Kumar SR, Kim A, Zlokovic BV (2000) Brain injury and cerebrovascular fibrin deposition correlate with reduced antithrombotic brain capillary functions in a hypertensive stroke model. J Cereb Blood Flow Metab 20(6):998–1009
Baumann E, Preston E, Slinn J, Stanimirovic D (2009) Post-ischemic hypothermia attenuates loss of the vascular basement membrane proteins, agrin and SPARC, and the blood-brain barrier disruption after global cerebral ischemia. Brain Res 1269:185–197
Lassmann H (2005) Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 15(3):217–222
Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7(3):115–121
Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H (1998) Multiple sclerosis: lessons from neuropathology. Semin Neurol 18(3):337–349
Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113(Pt 5):1477–1489
Kwon EE, Prineas JW (1994) Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 53(6):625–636
Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451(7182):1076–1081
Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, Probert L, Strickland S (2004) Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA 101(17):6698–6703
Paterson PY (1976) Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc 35(13):2428–2434
Inoue A, Koh CS, Shimada K, Yanagisawa N, Yoshimura K (1996) Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol 71(1–2):131–137
Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153(3):801–813
Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 92(24):11294–11298
Wakefield AJ, More LJ, Difford J, McLaughlin JE (1994) Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 47(2):129–133
Gay FW, Drye TJ, Dick GW, Esiri MM (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120(Pt 8):1461–1483
Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ (2007) Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130(Pt 11):2800–2815
Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bo L, van der Valk P, Barkhof F, de Vries HE (2005) Blood–brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 20(3):953–960
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726):1314–1318
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8(6):752–758
Saido TC, Iwata N (2006) Metabolism of amyloid beta peptide and pathogenesis of Alzheimer’s disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 54(4):235–253
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
Biffi A, Greenberg SM (2011) Cerebral amyloid angiopathy: a systematic review. J Clin Neurol 7(1):1–9
Altman R, Rutledge JC (2010) The vascular contribution to Alzheimer’s disease. Clin Sci (Lond) 119(10):407–421
Kalaria RN (1999) The blood–brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci 893:113–125
Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood–brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68(21):1809–1814
Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118(1):103–113
Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2007) Microvascular injury and blood–brain barrier leakage in Alzheimer’s disease. Neurobiol Aging 28(7):977–986
Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood–brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10(6):463–470
Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C (2005) Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer’s disease are centered on vessel walls. Am J Pathol 167(2):527–543
Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J Exp Med 204(8):1999–2008
Ryu JK, McLarnon JG (2008) A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med 13:2911–2925
van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36(12):2637–2641
Xu G, Zhang H, Zhang S, Fan X, Liu X (2008) Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 62(7):1070–1075
Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer’s disease brain and damage the blood–brain barrier. Eur J Clin Invest 32(5):360–371
Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM, Strickland S (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron 66(5):695–709
Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S (2010) Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci USA 107(50):21812–21817
Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci 30(45):14946–14954
Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX (2010) Is brain amyloid production a cause or a result of dementia of the Alzheimer’s type? J Alzheimers Dis 22(2):393–399
Cordonnier C, van der Flier WM (2011) Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 134(Pt 2):335–344
Cortes-Canteli M, Strickland S (2009) Fibrinogen, a possible key player in Alzheimer’s disease. J Thromb Haemost 7(Suppl 1):146–150
Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5(5):347–360
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444
Xie J, Itzkowitz SH (2008) Cancer in inflammatory bowel disease. World J Gastroenterol 14(3):378–389
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96(10):3302–3309
Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL (2002) Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62(23):6966–6972
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL (2007) Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110(1):133–141
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105(1):178–185
Palumbo JS, Degen JL (2010) Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res 125(Suppl 2):S39–S43
Palumbo JS, Degen JL (2007) Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res 120(Suppl 2):S22–S28
Wilberding JA, Ploplis VA, McLennan L, Liang Z, Cornelissen I, Feldman M, Deford ME, Rosen ED, Castellino FJ (2001) Development of pulmonary fibrosis in fibrinogen-deficient mice. Ann N Y Acad Sci 936:542–548
Ploplis VA, Wilberding J, McLennan L, Liang Z, Cornelissen I, DeFord ME, Rosen ED, Castellino FJ (2000) A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am J Pathol 157(3):703–708
Drew AF, Tucker HL, Liu H, Witte DP, Degen JL, Tipping PG (2001) Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 281(6):F1157–F1163
Cruz-Topete D, Iwaki T, Ploplis VA, Castellino FJ (2006) Delayed inflammatory responses to endotoxin in fibrinogen-deficient mice. J Pathol 210(3):325–333
Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16(8):887–896